The positive and negative syndrome scale (PANSS) for schizophrenia. In this review, we discuss the presentation, diagnosis and management of PDP. To obtain This site needs JavaScript to work properly. The levodopa equivalent daily dose and chlorpromazine equivalent daily dose were calculated using published and validated equivalence schemes- For the SCZ group: schizophrenia, according to DSM-IV-TR diagnosis criteria including a positive score criterion for hallucination (A2: characteristic symptoms) and a score up to three for the ‘hallucinatory behavior’ item of the - For the PD group: a diagnosis of Parkinson’s disease based on the UK Brain Bank criteria- An inability to understand the instructions because of language or an underlying severe pathology.- A primary diagnosis of any psychiatric disorder Axis I (including Substance-related Disorder, Mood Disorder and Anxiety Disorder), apart from schizophrenia in the SCZ group.The study was conducted according to good clinical practice.
A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson’s disease patients without dementia. Comparisons between independent groups were analyzed using the Student t-test or Mann-Whitney test when conditions of the t-test were not met (normality and homoscedasticity verified by the Fisher-Snedecor test) for quantitative variables. Table1 Hallucination scale in Parkinson’s disease Symptom Score None 0 Vivid dreams, illusions, sense of presence 1 Dreams encroaching on waking hours, occasional tolerable hallucinations 2 Regular evening and night time intrusive visual hallucinations 3 Psychosis in Parkinson’s disease 645 www.postgradmedj.com copyright. You can also search for this author in
The objectives were i) to describe the phenomenology of these clinical symptoms in those two specific populations, and ii) to compare their specificity in those two groups.We performed a multicenter study involving five psychiatric departments and two neurological departments in France during one year. J Neurol Neurosurg Psychiatry 82, 1219–1224, doi: 10.1136/jnnp.2010.234799 (2011).Rocca, P., Castagna, F., Mongini, T., Montemagni, C. & Bogetto, F. Relative contributions of psychotic symptoms and insight to quality of life in stable schizophrenia. J Neurol Sci 289, 12–17, doi: 10.1016/j.jns.2009.08.014 (2010).Inzelberg, R., Kipervasser, S. & Korczyn, A. D. Auditory hallucinations in Parkinson’s disease.
Expert Rev Clin Pharmacol. 1.1 Communication with people with Parkinson's disease and their carers. Internet Explorer). This result exemplifies the potential of the PSAS to systematically explore hallucinations in every modality.The prevalence of “presence hallucinations”, described by the “guardian angel” item of the PSAS, in PD is rather well-known, ranging from 34 to 40% in samples of consecutively examined patientsIt’s noteworthy that, despite this high percentage of presence hallucinations, the mean L-dopa equivalent daily dose (LEDD) was very close to the one reported by Fenelon Jaspers described this phenomenon in 1913, in patients suffering from dementia praecox (i.e. Name must be less than 100 characters
Neurology 64, 1404–1410, doi: 10.1212/01.wnl.0000158422.41380.82 (2005).Koehler, K. & Sauer, H. Jaspers’ sense of presence in the light of Huber’s basic symptoms and DSM-III. Eur Psychiatry 19, 15–20, doi: 10.1016/s0924-9338(03)00028-2 (2004).Woods, A., Jones, N., Alderson-Day, B., Callard, F. & Fernyhough, C. Experiences of hearing voices: analysis of a novel phenomenological survey.
Epub 2018 Apr 4.Bozymski KM, Lowe DK, Pasternak KM, Gatesman TL, Crouse EL.Ann Pharmacother. and JavaScript.Hallucinations have been described in various clinical populations, but they are neither disorder nor disease specific. Atypon Author Fénelon G. reports personal fees from Lundbeck and Teva Pharma, all outside the submitted work. Written consent is not required in this case. The description of hallucination impact on patients, using the repercussion index, could be of interest to define individualized treatment goals for patients.One of the limitations of this study is the cross-sectional design, which doesn’t allow for study of the evolution of hallucinations over time or their relations, which is of interest as underlined by different authorsThe phenomenological specificity of hallucinations regarding pathologies can contribute significantly towards their comprehension, and ongoing publicationsLowe, G. R. The phenomenology of hallucinations as an aid to differential diagnosis. Parkinson's disease psychosis (PDP) encompasses minor phenomena (illusions, passage hallucinations and presence hallucinations), visual and nonvisual hallucinations and delusions.